On May 1, 2026, FLUENT Corp., a vertically-integrated, multi-state cannabis company, entered into a definitive agreement with Legacy Therapeutics, LLC, pursuant to which Legacy will acquire 100% of the issued and outstanding equity interests in Cansortium Texas, LLC, a subsidiary of FLUENT. The transaction contemplates the sale of FLUENT’s Texas business operations, which includes Cansortium Texas’s license, cultivation, manufacturing, and delivery business in Schulenburg, Texas, as well as its Houston retail operations.
Pursuant to the terms of the Purchase Agreement, the purchase price payable by Legacy is equal to US$30 million, of which US$25 million will be payable at closing and an amount equal to US$2.5 million will be payable on each of the first and second anniversary of the closing date.
Cassels is acting as counsel to FLUENT.